Gastroenterology
Volume 118, Issue 4 , Pages 661-669 , April 2000

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa

  • Elly C. Klinkenberg-Knol

      Affiliations

    • Department of Gastroenterology, Free University Hospital, Amsterdam, The Netherlands
    • ,
  • Frits Nelis

      Affiliations

    • Department of Gastroenterology, Sophia Hospital, Zwolle, The Netherlands
    • ,
  • John Dent

      Affiliations

    • Department of Gastrointestinal Medicine, Royal Adelaide Hospital, Adelaide, Australia
    • ,
  • Pleun Snel

      Affiliations

    • Department of Gastroenterology, Slotervaart Hospital, Amsterdam, The Netherlands
    • ,
  • Brent Mitchell

      Affiliations

    • Department of Gastroenterology, Launceston Hospital, Launceston, Tasmania
    • ,
  • Peter Prichard

      Affiliations

    • Department of Gastroenterology and Hepatology, Epworth Hospital, Victoria, Australia
    • ,
  • David Lloyd

      Affiliations

    • St. Joseph's Health Centre, London, Ontario, Canada
    • ,
  • Niilo Havu

      Affiliations

    • Department of Safety Assessment, AstraZeneca, Södertälje, Sweden; and Departments of
    • ,
  • Madeline H. Frame

      Affiliations

    • Clinical Science
    • ,
  • Jonas Romàn

      Affiliations

    • Biostatistics
    • ,
  • Anders Walan

      Affiliations

    • Gastrointestinal Management and Strategy, AstraZeneca, Mölndal, Sweden
    • ,
  • Long–Term Study Group

Received 9 June 1999 ,Accepted 10 December 1999.

References 

  1. Bardhan KD, Naesdal J, Bianchi Porro G, Petrillo M, Lazzaroni RFC, Hinchcliffe RFC, et al. Treatment of refractory peptic ulcer with omeprazole or continued H2-receptor antagonists: a controlled clinical trial. Gut. 1991;32:435–438
  2. Tytgat GNJ, Lamers CBHW, Hameeteman W, Jansen JMBJ, Wilson JA. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther. 1987;1:31–38
  3. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(suppl 1):42–55
  4. Havu N, Mattsson H, Carlsson K, Lundell L, Carlsson E, Bräutigam J. Partial fundectomy results in hypergastrinemia and the development of gastric ECL cell carcinoids in the rat. (abstr) Scand J Gastroenterol. 1989;24(suppl 166):158
  5. Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike cell carcinoids in the rat. Gastroenterology. 1991;100:311–319
  6. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356–1370
  7. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022
  8. Klinkenberg EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994;121:161–167
  9. Lundell L, Abrahamsson H, Ruth M, Rydberg L, Lonroth H, Olbe L. Long-term results of a prospective randomized comparison of total fundic wrap (Nissen–Rosetti) or semifundoplication (Toupet) for gastroesophageal reflux. Br J Surg. 1996;83:830–835
  10. Johansson J, Johnsson F, Joelsson B, Floren CH, Walther B. Outcome 5 years after 360 degree fundoplication for gastroesophageal reflux disease. Br J Surg. 1993;80:46–49
  11. Sevier AC, Munger BL. Technical note: a silver method for paraffin sections of neural tissue. J Neuropathol Exp Neurol. 1965;24:130–135
  12. Grimelius L, Wilander E. Silver stains in the study of endocrine cells of the gut and pancreas. Invest Cell Pathol. 1980;3:3–12
  13. Rindi G, Buffa R, Sessa F, Tortora O, Solcia E. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells. Distribution, distinction from co-stored hormones/prohormones and relationship with argyrophil components of secretory granules. Histochemistry. 1986;85:19–28
  14. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of non-antral gastric endocrine growths in man. Digestion. 1988;41:185–200
  15. Garvey W, Fathi A, Bigelow F. Modified Steiner for the demonstration of spirochetes. J Histotechnol. 1985;1:15–17
  16. Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6:209–222
  17. Cochran WG. Sampling techniques. In: 3rd ed. New York: Wiley; 1977;p. 33 and 153
  18. Siewert JR, Feussner H, Walker SJ. Fundoplication: how to do it? Peri-esophageal wrapping as a therapeutic principal in gastroesophageal reflux prevention. World J Surg. 1992;16:326–334
  19. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. Ann Surg. 1986;204:9–20
  20. Lundell L, Dalenbäck J, Hattlebakk J, Janatuinen E, Levander K, Miettinen P, et al. Omeprazole or antireflux surgery in the long-term management of gastroesophageal reflux disease: results of a multicentre, randomised clinical trial. (abstr) Gastroenterology. 1998;114:A207
  21. Lundell L, Dalenbäck J, Hattlebakk J, Janatuinen E, Levander K, Miettinen P, et al. Outcome of open antireflux surgery as assessed in a Nordic Multicentre Prospective Clinical Trial. Eur J Surg. 1998;164:751–757
  22. Siewert JR, Stein HJ. What attitude should be adopted in failed antireflux procedures?. In:  Giuli R,  Galmiche JP,  Jamieson GG,  Scarpignato C editor. Proceedings of the International Organization for Statistical Studies on Diseases of the Esophagus. The esophagogastric junction. Paris, London, Rome: Libbey,; 1998;p. 820–824
  23. Luostarinen M. Nissen fundoplication for reflux esophagitis. Long-term clinical and endoscopic results in 109 of 127 consecutive patients. Ann Surg. 1993;217(4):329–337
  24. Viljakka M, Nevalainen J, Isolauri J. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand J Gastroenterol. 1997;32:766–772
  25. Schnell T, Sontag SJ. What is the incidence of development of Barrett's esophagus?. In:  Giuli R,  Galmiche JP,  Jamieson GG,  Scarpignato C editor. Proceedings of the International Organization for Statistical Studies on Diseases of the Esophagus. The esophagogastric junction. Paris, London, Rome: Libbey,; 1998;p. 933–938
  26. Spechler SJ. The columnar-lined esophagus. History, terminology and clinical issues. Gastroenterol Clin North Am. 1997;26:455–466
  27. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G, et al. Triglycerides, a major coronary risk factor in elderly man. A study of men born in 1913. Eur Heart J. 1991;12:700–704
  28. Lapidus L. Ischaemic heart disease, stroke and total mortality in women—results from a prospective population study in Gothenburg, Sweden. Thesis. Department of Medicine II. Gothenburg, Sweden: Sahlgrenska Hospital, Gothenburg University,; 1985;
  29. MONICA Project WHO. geographic variation in mortality from cardiovascular diseases. World Health Stat Q. 1987;40:171–184
  30. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion. 1992;51(suppl 1):59–67
  31. Carlsson R, Galmiche J-P, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997;11:473–482
  32. Feldman M, Cryer B, McArthur KE, Lee E. Relationship between severity of H. pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology. 1996;110:1386–1394
  33. Ruiz B, Correa P, Fontham ETH, Ramakrishan T. Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol. 1996;105:96–101
  34. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41:452–458
  35. Schenk B, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. Helicobacter pylori, GERD, and efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:884–887
  36. Hattlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther. 1997;11:1093–1099
  37. Carlsson R, Bate CM, Dent J, Frison L, Gnarpe H, Hallerbäck B, et al. Does the presence of Helicobacter pylori infection influence the response to acid inhibition therapy in patients with gastroesophageal reflux disease? Thesis. Gastroesophageal reflux disease, a study of pathophysiology, clinical diagnosis and management. Gothenburg, Sweden: Gothenburg University,; 1998;
  38. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525–1528
  39. Eissele R, Brunner G, Bimon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology. 1997;112:707–717
  40. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology. 1999;117:319–326

☆ Address requests for reprints to: Elly C. Klinkenberg-Knol, M.D., Ph.D., Department of Gastroenterology, Free University Hospital, De Boelelaan 1117, 1007 MB, Amsterdam, The Netherlands. e-mail: EC.Klinkenberg@azvu.nl; fax: (31) 20-444-0554.

☆☆ Supported by Astra Hässle AB, Mölndal, Sweden.

PII: S0016-5085(00)70135-1

Gastroenterology
Volume 118, Issue 4 , Pages 661-669 , April 2000

Article Tools

* Image Usage & Resolution